IRE strengthens its leadership in radiopharmaceutical production with the arrival of the 30 MeV IBA cyclotron at its site

Latest stories

IRE ELiT and Grand Pharmaceutical (China) Co., Ltd. announce partnership for Galli Eo (Gallium-68 generator) distribution in China

IRE ELiT and PI Medical Diagnostic Equipment announce commercial partnership for Galli Ad generator in the Netherlands and Flanders

IRE moves to 100% LEU (Low Enriched Uranium) conversion

The fight against cancer intensified thanks to SCK CEN and the IRE

SMART takes critical step towards the production of medical isotope Mo-99 without uranium

SMART takes critical step towards the production of medical isotope Mo-99 without uranium

Cardinal Health™ Nuclear & Precision Health Solutions and IRE ELiT support the growing demand for Ga-68 labeled radiopharmaceuticals

IRE ELiT and ROTOP Pharmaka enter into a distribution partnership in Germany for 68Germanium / 68Gallium generator

IBA selected to equip IRE’s new radioisotope production unit dedicated to cancer diagnosis

IRE supplies a first commercial batch of LEU-based Mo-99

IRE and SCK CEN Partnership on lutetium-177 production: a ray of hope for prostate cancer treatment

World Cancer Day : IRE ELiT wants to encourage the research and development of radiopharmaceuticals applications for cancer imaging

Contact us

Bérénice Pignol

IRE - IRE ELiT

berenice.pignol@ire-elit.eu 0471 70.62.44

Ariane Goossens

Whyte Corporate Affairs

ag@whyte.be 02 738 06 20

About IRE and IRE ELiT

About IRE

The Institute for Radioelements (IRE) is a public utility foundation primarily focused on producing radioisotopes for diagnostic and therapeutic applications in nuclear medicine. IRE is the global leader in Molybdenum-99 production, the parent isotope of metastable Technetium-99m, the most widely used isotope in nuclear medicine for various examinations (heart, bones, lungs, thyroid, brain, kidneys, etc.). Beyond its production activities, IRE contributes to environmental protection and monitoring through its IRE Lab division, offering services such as radioactivity measurement in various samples, radiological characterization of waste and contaminated materials, and consultancy and technical support in radiological and nuclear fields.

IRE ELiT, the innovation subsidiary founded in 2010, develops radiopharmaceuticals for cancer imaging and treatment. Together, IRE and IRE ELiT employ more than 270 people. More information: www.ire.eu

Contact